ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak

INTerpath-001 Phase 3 melanoma data leaked accidentally ahead of ESMO 2026. Intismeran autogene combined with Keytruda met the primary endpoint, with an RFS hazard ratio of 0.58, corresponding to a 42% reduction in the risk of recurrence or death.